Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency

被引:61
作者
Daci, E [1 ]
Verstuyf, A [1 ]
Moermans, K [1 ]
Bouillon, R [1 ]
Carmeliet, G [1 ]
机构
[1] Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, Louvain, Belgium
关键词
plasminogen activator inhibitor 1; mice; ovariectomy; bone turnover; bone histomorphometry;
D O I
10.1359/jbmr.2000.15.8.1510
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone turnover requires the interaction of several proteases during the resorption phase. Indirect evidence suggests that the plasminogen activator/plasmin pathway is involved in bone resorption and turnover, and recently we have shown that this cascade plays a role in the degradation of nonmineralized bone matrix in vitro. To elucidate the role of the plasminogen activator inhibitor 1 (PAI-1) in bone turnover in vivo, bone metabolism was analyzed in mice deficient in the expression of PAI-1 gene (PAI-1(-/-)) at baseline (8-week-old mice) and 4 weeks after ovariectomy (OVX) or sham operation (Sham) and compared with wild-type (WT) mice. PAI-1 inactivation was without any effect on bone metabolism at baseline or in Sham mice. However, significant differences were observed in the response of WT and PAI-1(-/-) mice to ovariectomy. The OVX WT mice showed, as expected, decreased trabecular bone volume (BV/TV) and increased osteoid surface (OS/BS) and bone formation rate (BFR), as assessed by histomorphometric analysis of the proximal tibial metaphysis. In contrast, no significant change in any of the histomorphometric variables studied was detected in PAI-1(-/-) mice after ovariectomy. As a result, the OVX PAI-1(-/-) had a significantly higher BV/TV, lower OS/BS, lower mineral apposition rate (MAR) and BFR when compared with the OVX WT mice. However, a comparable decrease in the cortical thickness was observed in OVX PAI-1(-/-) and WT mice. In addition, the cortical mineral content and density assessed in the distal femoral metaphysis by peripheral quantitative computed tomography (pQCT), decreased significantly after ovariectomy, without difference between PAI-1(-/-) mice and WT mice. In conclusion, basal bone turnover and bone mass are only minimally affected by PAI-1 inactivation. In conditions of estrogen deficiency, PAI-1 inactivation protects against trabecular bone loss but does not affect cortical bone loss, suggesting a site-specific role for PAI-1 in bone turnover.
引用
收藏
页码:1510 / 1516
页数:7
相关论文
共 30 条
[1]  
ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54
[2]   TRANSFORMING GROWTH-FACTOR-BETA INHIBITS PLASMINOGEN-ACTIVATOR (PA) ACTIVITY AND STIMULATES PRODUCTION OF UROKINASE-TYPE PA, PA INHIBITOR-1 MESSENGER-RNA, AND PROTEIN IN RAT OSTEOBLAST-LIKE CELLS [J].
ALLAN, EH ;
ZEHEB, R ;
GELEHRTER, TD ;
HEATON, JH ;
FUKUMOTO, S ;
YEE, JA ;
MARTIN, TJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1991, 149 (01) :34-43
[3]   Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].
Ammann, P ;
Rizzoli, R ;
Bonjour, JP ;
Bourrin, S ;
Meyer, JM ;
Vassalli, P ;
Garcia, I .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703
[4]   INVOLVEMENT OF THE PLASMIN SYSTEM IN DISSOCIATION OF THE INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX [J].
CAMPBELL, PG ;
NOVAK, JF ;
YANOSICK, TB ;
MCMASTER, JH .
ENDOCRINOLOGY, 1992, 130 (03) :1401-1412
[5]   Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation [J].
Carmeliet, P ;
Moons, L ;
Lijnen, HR ;
Baes, M ;
Lemaitre, V ;
Tipping, P ;
Drew, A ;
Eeckhout, Y ;
Shapiro, S ;
Lupu, F ;
Collen, D .
NATURE GENETICS, 1997, 17 (04) :439-444
[6]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .2. EFFECTS ON HEMOSTASIS, THROMBOSIS, AND THROMBOLYSIS [J].
CARMELIET, P ;
STASSEN, JM ;
SCHOONJANS, L ;
REAM, B ;
VANDENOORD, JJ ;
DEMOL, M ;
MULLIGAN, RC ;
COLLEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2756-2760
[7]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .1. GENERATION BY HOMOLOGOUS RECOMBINATION AND CHARACTERIZATION [J].
CARMELIET, P ;
KIECKENS, L ;
SCHOONJANS, L ;
REAM, B ;
VANNUFFELEN, A ;
PRENDERGAST, G ;
COLE, M ;
BRONSON, R ;
COLLEN, D ;
MULLIGAN, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2746-2755
[8]   GENE TARGETING AND GENE-TRANSFER STUDIES OF THE PLASMINOGEN/PLASMIN SYSTEM - IMPLICATIONS IN THROMBOSIS, HEMOSTASIS, NEOINTIMA FORMATION, AND ATHEROSCLEROSIS [J].
CARMELIET, P ;
COLLEN, D .
FASEB JOURNAL, 1995, 9 (10) :934-938
[9]   The role of the plasminogen system in bone resorption in vitro [J].
Daci, E ;
Udagawa, N ;
Martin, TJ ;
Bouillon, R ;
Carmeliet, G .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (06) :946-952
[10]   PLASMINOGEN-ACTIVATOR REGULATION IN OSTEOBLASTS - PARATHYROID-HORMONE INHIBITION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND ITS MESSENGER-RNA [J].
FUKUMOTO, S ;
ALLAN, EH ;
YEE, JA ;
GELEHRTER, TD ;
MARTIN, TJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 152 (02) :346-355